In vitro efficacy of artemisinin-based treatments against SARS-CoV-2

Yuyong Zhou, Kerry Gilmore, Santseharay Ramirez, Eva Settels, Karen A. Gammeltoft, Long V. Pham, Ulrik Fahnøe, Shan Feng, Anna Offersgaard, Jakob Trimpert, Jens Bukh, Klaus Osterrieder, Judith M. Gottwein*, Peter H. Seeberger

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

65 Citations (Scopus)
61 Downloads (Pure)

Abstract

Effective and affordable treatments for patients suffering from coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are needed. We report in vitro efficacy of Artemisia annua extracts as well as artemisinin, artesunate, and artemether against SARS-CoV-2. The latter two are approved active pharmaceutical ingredients of anti-malarial drugs. Concentration–response antiviral treatment assays, based on immunostaining of SARS-CoV-2 spike glycoprotein, revealed that treatment with all studied extracts and compounds inhibited SARS-CoV-2 infection of VeroE6 cells, human hepatoma Huh7.5 cells and human lung cancer A549-hACE2 cells, without obvious influence of the cell type on antiviral efficacy. In treatment assays, artesunate proved most potent (range of 50% effective concentrations (EC50) in different cell types: 7–12 µg/mL), followed by artemether (53–98 µg/mL), A. annua extracts (83–260 µg/mL) and artemisinin (151 to at least 208 µg/mL). The selectivity indices (SI), calculated based on treatment and cell viability assays, were mostly below 10 (range 2 to 54), suggesting a small therapeutic window. Time-of-addition experiments in A549-hACE2 cells revealed that artesunate targeted SARS-CoV-2 at the post-entry level. Peak plasma concentrations of artesunate exceeding EC50 values can be achieved. Clinical studies are required to further evaluate the utility of these compounds as COVID-19 treatment.

Original languageEnglish
Article number14571
JournalScientific Reports
Volume11
ISSN2045-2322
DOIs
Publication statusPublished - 2021

Bibliographical note

Publisher Copyright:
© 2021, The Author(s).

Cite this